Mobile

A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Re...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003091-77

A Phase 3 Study to Compare Avelumab Given Alone or Given in Combination with Pegylated Liposomal Doxorubicin Compared to Pegylated Liposomal Doxorubicin Given Alone Patients with Platinum-Resistant/Refractory Ovarian Cancer

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging OS in patients with platinum -resistant/platinum-refractory ovarian cancer.

Critère d'inclusion

  • Ovarian Cancer